Low ALT, a marker of sarcopenia and frailty, is associated with shortened survival amongst myelodysplastic syndrome patients: A retrospective study.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
25 Apr 2023
25 Apr 2023
Historique:
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
ppublish
Résumé
Myelodysplastic Syndrome (MDS) is a common blood dyscrasia that mainly affects the elderly population. Several prognostic scores are available utilizing blood count variables and cytogenetic abnormalities, targeting the disease rather than the patient. Sarcopenia and frailty are associated with shortened survival rates in various disease states. Low Alanine Aminotransferase (ALT) levels are a marker of lowered muscle mass and frailty status. This study aimed to examine the correlation between low ALT levels and prognosis in MDS patients. This is a retrospective cohort study. We obtained the demographic, clinical, and laboratory data of patients in a tertiary hospital. Univariate and multivariate models were used to investigate the potential relationship between low ALT level and survival. The final study included 831 patients (median age 74.3 years, Interquartile range 65.6-81.8), and 62% were males. The median ALT level was 15 international units (IU)/L and 233 patients (28%) had low ALT levels (<12 IU/L). Univariate analysis showed that low ALT levels were associated with a 25% increase in mortality (95% confidence interval [CI]: 1.05-1.50, P = .014). A multivariate model controlling for age, sex, body mass index, hemoglobin and albumin concentrations, and low ALT levels was still significantly associated with increased mortality (hazard ratio [HR] = 1.25, 95% CI: 1.01-1.56, P = .041). Low ALT levels were associated with increased mortality among patients with MDS. Impact: Using ALT as a frailty metric may allow patient-centered, personalized care in this patient population. A low ALT level reflects the pre-morbid robustness of patients and is not intended to replace disease-centered characteristics.
Identifiants
pubmed: 37115069
doi: 10.1097/MD.0000000000033659
pii: 00005792-202304250-00028
pmc: PMC10146076
doi:
Substances chimiques
Alanine Transaminase
EC 2.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e33659Informations de copyright
Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding and conflicts of interest to disclose.
Références
Zeidan AM, Shallis RM, Wang R, et al. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1–15.
Tsuruda K, Hasegawa H, Fuchigami M, et al. [Classification and clinical findings of myelodysplastic syndromes]. Rinsho Byori. 2014;62:359–68.
Santini V, Prebet T, Fenaux P, et al. Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leuk Res. 2014;38:1381–91.
Bouchla A, Thomopoulos TP, Papageorgiou SG, et al. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine. Epigenomics. 2021;13:1129–43.
Kataria A, Jaegerskog E, Jindal R, et al. MDS-447 a systematic literature review of the economic burden in patients with myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S315.
Haroun F, Solola SA, Nassereddine S, et al. PD-1 signaling and inhibition in AML and MDS. Ann Hematol. 2017;96:1441–8.
Alonso-Fernandez-Gatta M, Martin-Garcia A, Martin-Garcia AC, et al. Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome. Br J Haematol. 2021;195:536–41.
Nazha A. The MDS genomics-prognosis symbiosis. Hematology Am Soc Hematol Educ Program. 2018;2018:270–6.
Scalzulli E, Pepe S, Colafigli G, et al. Therapeutic strategies in low and high-risk MDS: what does the future have to offer? Blood Rev. 2021;45:100689.
Gurnari C, Piciocchi A, Soddu S, et al. Myelodysplastic syndromes with del(5q): a real-life study of determinants of long-term outcomes and response to lenalidomide. Blood Cancer J. 2022;12:132.
Lieu YK, Liu Z, Ali AM, et al. SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2022;119:1–11.
Starkman R, Alibhai S, Wells RA, et al. An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. Leukemia. 2020;34:1394–406.
Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454.
Landi F, Calvani R, Tosato M, et al. Age-related variations of muscle mass, strength, and physical performance in community-dwellers: results from the milan EXPO survey. J Am Med Dir Assoc. 2017;18:88.e17–24.
Marzetti E, Calvani R, Tosato M, et al. Sarcopenia: an overview. Aging Clin Exp Res. 2017;29:11–7.
Beaudart C, McCloskey E, Bruyère O, et al. Sarcopenia in daily practice: assessment and management. BMC Geriatr. 2016;16:1–10.
de Vries NM, Staal JB, van der Wees PJ, et al. Patient-centred physical therapy is (cost-) effective in increasing physical activity and reducing frailty in older adults with mobility problems: a randomized controlled trial with 6 months follow-up. J Cachexia Sarcopenia Muscle. 2016;7:422–35.
Sánchez-García S, García-Peña C, Salvà A, et al. Frailty in community-dwelling older adults: association with adverse outcomes. Clin Interv Aging. 2017;12:1003–11.
Pongpipatpaiboon K, Kondo I, Onogi K, et al. Preliminary study on prevalence and associated factors with sarcopenia in a geriatric hospitalized rehabilitation setting. J Frailty Aging. 2018;7:47–50.
Gringauz I, Weismann J, Justo D, et al. Alanine aminotransferase blood levels and rehabilitation outcome in older adults following hip fracture surgery. Int J Rehabil Res. 2018;41:41–6.
Liu P, Hao Q, Hai S, et al. Sarcopenia as a predictor of all-cause mortality among community-dwelling older people: a systematic review and meta-analysis. Maturitas. 2017;103:16–22.
Vetrano DL, Pisciotta MS, Laudisio A, et al. Sarcopenia in Parkinson disease: comparison of different criteria and association with disease severity. J Am Med Dir Assoc. 2018;19:523–7.
Tabara Y, Kohara K, Ochi M, et al. Association of office-based frailty score with hypertensive end organ damage in the J-SHIPP cross-sectional study. Int J Cardiol. 2016;216:25–31.
Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic obesity study. Hepatology. 2014;59:1772–8.
Hirose D, Hanyu H, Fukasawa R, et al. Frailty and sarcopenia in subjects with Alzheimer’s disease with or without cerebrovascular disease. Geriatr Gerontol Int. 2016;16:1235–6.
Cox MM, Nelson DL. Lehninger Principles of Biochemistry. Sixth. Springer Nature Switzerland AG. Part of Springer Nature: W.H.Freeman & Co Ltd; 2013.
Peltz-Sinvani N, Klempfner R, Ramaty E, et al. Low ALT levels independently associated with 22-year all-cause mortality among coronary heart disease patients. J Gen Intern Med. 2016;31:209–14.
Lasman N, Shalom M, Turpashvili N, et al. Baseline low ALT activity is associated with increased long-term mortality after COPD exacerbations. BMC Pulm Med. 2020;20:1–6.
Itelman E, Segev A, Ahmead L, et al. Low ALT values amongst hospitalized patients are associated with increased risk of hypoglycemia and overall mortality: a retrospective, big-data analysis of 51 831 patients. QJM. 2022;114:843–7.
Anani S, Goldhaber G, Brom A, et al. Frailty and sarcopenia assessment upon hospital admission to internal medicine predicts length of hospital stay and re-admission: a prospective study of 980 patients. J Clin Med. 2020;9:1–12.
Segev A, Itelman E, Avaky C, et al. Low ALT levels associated with poor outcomes in 8700 hospitalized heart failure patients. J Clin Med. 2020;9:1–10.
Segev A, Itelman E, Beigel R, et al. Low ALT levels are associated with poor outcomes in acute coronary syndrome patients in the intensive cardiac care unit. J Cardiol. 2022;79:385–90.
Portal D, Melamed G, Segal G, et al. Sarcopenia as manifested by L3SMI is associated with increased long-term mortality amongst internal medicine patients-a prospective cohort study. J Clin Med. 2022;11:3500.
Portal D, Hofstetter L, Eshed I, et al. L3 skeletal muscle index (L3SMI) is a surrogate marker of sarcopenia and frailty in non-small cell lung cancer patients. Cancer Manag Res. 2019;11:2579–88.
Cluzeau T, Loschi M, Fenaux P, et al. Personalized medicine for TP53 mutated myelodysplastic syndromes and acute myeloid leukemia. Int J Mol Sci. 2021;22:1–9.
Santini V. Advances in myelodysplastic syndrome. Curr Opin Oncol. 2021;33:681–6.
Morley JE. Frailty and sarcopenia in elderly. Wien Klin Wochenschr. 2016;128(Suppl 7):439–45.
Longobucco Y, Benedetti C, Tagliaferri S, et al. Proactive interception and care of frailty and multimorbidity in older persons: the experience of the European innovation partnership on active and healthy ageing and the response of parma local health trust and lab through European projects. Acta Biomed. 2019;90:364–74.
Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther. 2012;92:332–9.
Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47:1363–70.
Elinav E, Ackerman Z, Maaravi Y, et al. Low alanine aminotransferase activity in older people is associated with greater long-term mortality. J Am Geriatr Soc. 2006;54:1719–24.
Le Couteur DG, Blyth FM, Creasey HM, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65:712–7.
Ramaty E, Maor E, Peltz-Sinvani N, et al. Low ALT blood levels predict long-term all-cause mortality among adults. a historical prospective cohort study. Eur J Intern Med. 2014;25:919–21.